Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: Sensitivity to antagonism by quadazocine, naltrindole and β-funaltrexamine

Drug and Alcohol Dependence

Volumn 70, Issue 1, 2003, Pages 17-27

  Negus, S Stevens ^a   Brandt, Michael R ^a   Gatch, Michael B ^a   Mello, Nancy K ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Heroin; Nociception; Rhesus monkeys; Schedule controlled responding

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR ANTAGONIST; DIAMORPHINE; HOT WATER; MORPHINE; MORPHINE 6 ACETATE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; QUADAZOCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; FEMALE; FOOD; IN VIVO STUDY; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RHESUS MONKEY; THERMAL EXPOSURE;

ANIMALS; AZOCINES; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD; HEAT; HEROIN; MACACA MULATTA; MORPHINE; MORPHINE DERIVATIVES; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT;

MACACA MULATTA; RODENTIA;

EID: 0037401514     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(02)00331-9     Document Type: Article

References (47)

1. Bertalmio A.J., Medzihradsky F., Winger G., Woods J.H. Differential influence of N-dealkylation on the stimulus properties of some opioid agonists. J. Pharmacol. Exp. Ther. 261:1992;278-284.
2. 2 analysis. J. Pharmacol. Exp. Ther. 243:1987;591-597.
3. Bowen C.A., Fischer B.D., Mello N.K., Negus S.S. Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys. J. Pharmacol. Exp. Ther. 302:2002;264-273.
4. Brandt M.R., Furness M.S., Mello N.K., Rice K.C., Negus S.S. Antinociceptive effects of ∂-opioid agonists in rhesus monkeys: effects on chemically induced thermal hypersensitivty. J. Pharmacol. Exp. Ther. 296:2001;939-946.
5. Dykstra L.A., Gmerek D.E., Winger G., Woods J.H. Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242:1987;421-427.
6. Emmerson P.J., Liu M.-R., Woods J.H., Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271:1994;1630-1637.
7. Gatch M.B., Negus S.S., Butelman E.R., Mello N.K. Antinociceptive effects of cocaine/opioid combinations in rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;1346-1354.
8. Gatch M.B., Negus S.S., Bergman J., Mello N.K. Antagonism of levorphanol-induced antinociception and respiratory depression by naloxonazine in rhesus monkeys. Eur. J. Pharmacol. 298:1996;31-36.
9. Gatch M.B., Negus S.S., Mello N.K., Archer S., Bidlack J.M. Effects of the structurally novel opioid 14 a, 14′ b-[Dithiobis [(2-oxo-2, 1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys. J. Pharmacol. Exp. Ther. 278:1996;1282-1289.
10. Gutstein H.B., Akil H. Opioid analgesics. Hardman J.G., Limbird L.E. The Pharmacological Basis of Therapeutics. 10th ed:2001;569-619 McGraw-Hill, New York.
11. Harrigan S.E., Downs D.A. Self-administration of heroin, acetylmethadol, morphine and methadone in rhesus monkeys. Life Sci. 22:1978;619-623.
12. Hartvig P., Bergstrom K., Lindberg B., Lundberg P.O., Lundqvist H., Langstrom B., Svard H., Rane A. Kinetics of 11C-labeled opiates in the brain of rhesus monkeys. J. Pharmacol. Exp. Ther. 230:1984;250-255.
13. Inturissi C.E., Schultz M., Shin S., Umans J.G., Angel L., Simon E. Evidence from opioid binding sites that heroin acts through its metabolites. Life Sci. 33:(Suppl 1):1983;773-776.
14. Inturrisi C.E., Max M.B., Foley K.M., Shin S.-U., Houde R.W. The pharmacokinetics of heroin in patients with chronic pain. New Engl. J. Med. 310:1984;1213-1217.
15. Kaiko R.F., Wallenstein S.L., Rogers A.G., Grabinski P.Y., Houde R.W. Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. New Engl. J. Med. 304:1981;1501-1505.
16. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction. 1993;Raven Press, New York.
17. Kishioka S., Paronis C.A., Woods J.H. Acute dependence on, but tolerance to, heroin and morphine as measured by respiratory effects in rhesus monkeys. Eur. J. Pharmacol. 398:2000;121-130.
18. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 11:1988;308-314.
19. Martin T.J., Hairston C.T., Lutz P.O., Harris L.S., Porreca F. Anti-allodynic actions of intravenous opioids in the nerve-injured rat: potential utility of heroin and dihyroetorphine against neuropathic pain. Eur. J. Pharmacol. 357:1998;25-32.
20. Moerschbaecher J.M., Thompson D.M., Winsauer P.J. Effects of opioids and phencyclidine in combination with naltrexone on the acquisition and performance of response sequences in monkeys. Pharmacol. Biochem. Behav. 22:1985;1061-1069.
21. Negus S.S., Burke T.F., Medzihradsky F., Woods J.H. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J. Pharmacol. Exp. Ther. 267:1993;896-903.
22. Negus S.S., Butelman E.R., Ai Y., Woods J.H. Prostaglandin E2-induced hyperalgesia and its reversal by morphine in the warm-water tail-withdrawal procedure in rhesus monkeys. J. Pharmacol. Exp. Ther. 266:1993;1355-1363.
23. Negus S.S., Butelman E.R., Chang K.J., DeCosta B.R., Winger G., Wood J.H. Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J. Pharmacol. Exp. Ther. 270:1994;1025-1034.
24. Negus S.S., Gatch M.B., Mello N.K. Effects of mu opioid agonists alone and in combination with cocaine and d-amphetamine in rhesus monkeys trained to discriminate cocaine. Neuropsychopharmacology. 18:1998;325-338.
25. Negus, S.S., Zuzga, D.S.,Mello, N.K., 2002a. Sex differences in opioid antinociception in rhesus monkeys: Antagonism of fentanyl and U50 488 by quadazocine. J. Pain 3, 218-226.
26. Negus, S.S., Mello, N.K., Linsenmayer, D.C., Jones, R.M., Portoghese, P.S., 2002b. Kappa opioid antagonist effects of the novel kappa antagonist 5′-Guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology 163, 412-419.
27. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin and methadone after carotid injection. Science. 178:1972;984-986.
28. Pitts R.C., West J.P., Hapke D.M., Morgan D., Dykstra L.A., Picker M.J. Opioids and rate of positively reinforced behavior. II. Antagonism by β-funaltrexamine. Exp. Clin. Psychopharmacol. 4:1996;389-395.
29. Rady J.J., Roerig S.C., Fujimoto J.M. Heroin acts on different opioid receptors than morphine in swiss webster and ICR mice to produce antinociception. J. Pharmacol. Exp. Ther. 256:1991;448-457.
30. Rady J.J., Takemori A.E., Portoghese P.S., Fujimoto J.M. Supraspinal delta receptor subtype activity of heroin and 6-monoacetymorphine in swiss webster mice. Life Sci. 55:1994;603-609.
31. Rady J.J., Elmer G.I., Fujimoto J.M. Opioid receptor selectivity of heroin given intracerebroventricularly differs in six strains of inbred mice. J. Pharmacol. Exp. Ther. 288:1999;438-445.
32. Rowlett J.K., Spealman R.D., Platt D.M. Cocaine-like discriminative stimulus effects of heroin in squirrel monkeys: role of active metabolites and opioid receptor mechanisms. Psychopharmacology. 150:2000;191-199.
33. Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Can. J. Physiol. Pharmacol. 64:1986;1-6.
34. Selley D.E., Cao C.C., Sexton T., Schwegel J.A., Martin T.J., Childers S.R. Mu opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem. Pharmacol. 62:2001;447-455.
35. Tallarida R.J., Murray R.B. Pharmacologic Calculation System PHARM/PCS 4.2 User Guide Supplement, MicroComputer Specialist, 1986-1990. 1987;Springer-Verlag New York, New York. Based on: Manual of Pharmacologic Calculations with Computer Programs.
36. Umans J.G., Inturissi C.E. Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice. J. Pharmacol. Exp. Ther. 218:1981;409-415.
37. Vivian J.A., Kishioka S., Butelman E.R., Broadbear J., Lee K.O., Woods J.H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR141716A. J. Pharmacol. Exp. Ther. 286:1998;697-703.
38. Walker E.A., Tiano M.J., Benyas S.I., Dykstra L.A., Picker M.J. Naltrexone and β-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology. 144:1999;45-53.
39. Walker E.A., Zernig G., Woods J.H. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J. Pharm. Exp. Ther. 273:1995;1345-1352.
40. Walker E.A., Zernig G., Young A.M. In vivo apparent affinity and efficacy estimates for μ opiates in a rat tail-withdrawal assay. Psychopharmacology. 136:1998;15-23.
41. Way E.L., Kemp J.W., Young J.M., Grassetti D.R. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J. Pharmacol. Exp. Ther. 129:1960;144-155.
42. Winger G., Woods J.H. The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alc. Depend. 62:2001;181-189.
43. Young A.M., Swain H.H., Woods J.H. Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. Psychopharmacology. 74:1981;329-335.
44. Zernig G., Butelman E.R., Lewis J.W., Walker E.A., Woods J.H. In vivo determination of μ opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharm. Exp. Ther. 269:1994;57-65.
45. Zernig G., Issaevitch T. Software for the calculation of agonist efficacy and apparent in vivo affinity by simultaneous analysis of several dose-response curves. 1995;Wolfram Research, Champaign, IL.
46. Zernig G., Issaevitch T., Woods J.H. Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J. Pharmacol. Tox. Meth. 35:1996;223-237.
47. Zernig G., Lewis J.W., Woods J.H. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology. 129:1997;233-242.